drugset / Trial / NCT03535298
Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS
RandomizedParallel-groupOpen-labelTreatment
Summary
The DELIVER-MS study seeks to answer the question: Does early treatment with highly effective DMT improve the prognosis for people with MS? This is an area of significant controversy and no data currently exist to guide treatment choices for patients and clinicians. The study results will help guide overall treatment philosophy and will be applicable not only to a wide range of existing therapies but also to new therapies, meeting a significant unmet need in patient decision making and aiding the decision for medication approval by third parties.
Timeline
- Start
- 2019-01-03
- Primary completion
- 2027-07-30
- Completion
- 2027-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alemtuzumab | Monoclonal antibody | — | — |
| Subject | BAF312 | Unknown | — | — |
| Subject | Cladribine | Small molecule | — | — |
| Subject | Diroximel fumarate | Small molecule | — | — |
| Subject | Fingolimod | Small molecule | — | — |
| Subject | Glatiramer Acetate | Small molecule | — | — |
| Subject | Interferon beta-1a | Protein / enzyme biologic | — | — |
| Subject | Interferon beta-1b | Protein / enzyme biologic | — | — |
| Subject | Ocrelizumab | Monoclonal antibody | — | — |
| Subject | Ofatumumab | Monoclonal antibody | — | — |
| Subject | Ozanimod | Small molecule | — | — |
| Subject | Ponesimod | Small molecule | — | — |
| Subject | Rituximab | Monoclonal antibody | — | — |
| Subject | Teriflunomide | Small molecule | — | — |
| Subject | Ublituximab | Monoclonal antibody | — | — |
| Subject | dimethyl fumarate | Unknown | — | — |
| Subject | monomethyl fumarate | Small molecule | — | — |
| Subject | natalizumab | Monoclonal antibody | — | — |
| Subject | peginterferon beta-1a | Protein / enzyme biologic | — | — |